In the combination phase , adverse events that were reported at least 10 % more frequently with olaparib plus chemotherapy than with chemotherapy alone were alopecia ( 60 [ 74 % ] of 81 vs 44 [ 59 % ] of 75 ) , nausea ( 56 [ 69 % ] vs 43 [ 57 % ] ) , neutropenia ( 40 [ 49 % ] vs 29 [ 39 % ] ) , diarrhoea ( 34 [ 42 % ] vs 20 [ 27 % ] ) , headache ( 27 [ 33 % ] vs seven [ 9 % ] ) , peripheral neuropathy ( 25 [ 31 % ] vs 14 [ 19 % ] ) , and dyspepsia ( 21 [ 26 % ] vs 9 [ 12 % ] ) ; most were of mild-to-moderate intensity .